SCHEMBL13524933

SCHEMBL13524933

COc1cccc(-c2cnc(Nc3cc(N4CCN(C)CC4)ccn3)s2)c1

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.62
CHEK1 O14757 18/20 0.62
CDK7 P50613 5/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13524904 0.87 CHEK1 (0.71) KDRCHEK1CDK7
SCHEMBL13524930 0.87 CHEK1 (0.65) KDRCHEK1CDK7
SCHEMBL13524906 0.86 CHEK1 (0.64) KDRCHEK1CDK7
SCHEMBL13524958 0.85 CHEK1 (0.64) CHEK1CDK7
SCHEMBL13524944 0.85 CHEK1 (0.64) KDRCHEK1CDK7
SCHEMBL13524911 0.84 CHEK1 (0.67) KDRCHEK1CDK7
SCHEMBL13524905 0.84 CHEK1 (0.61) CHEK1CDK7
SCHEMBL13524940 0.83 CHEK1 (0.65) CHEK1CDK7
SCHEMBL13524943 0.83 CHEK1 (0.62) CHEK1CDK7
SCHEMBL13524925 0.83 CHEK1 (0.61) CHEK1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009987-A1 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MERCK SHARP & DOHME LIMITED (GB) 2010-01-14 US disclosed
US-20100009987-A1 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MERCK SHARP & DOHME LIMITED (GB) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009987-A1 AMINOTHIAZOLE DERIVATIVES AS INHIBITORS OF MARK MAPT, MARK4, MARK3 KDR 3396/4885CHEK1 494/4885CDK7 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.